Neurocysticercosis (NCC) is the commonest cause of childhood acquired epilepsy in developing countries. The use of cysticidal therapy in NCC, except "single lesion NCC," is still debated in view of its doubtful usefulness and potential adverse effects. Children presenting with first episode of seizure or acute focal neurological deficit without fever were screened for NCC and received appropriate therapy (followup done for 1 year to look for the response and side effects). The prevalence of NCC was 4.5%. Most common presenting feature was generalized seizure and commonest imaging finding was single small enhancing lesion in the parietal lobe. Abnormal EEG and CSF abnormalities were found in almost half of the children. The response to therapy was very good with infrequent recurrence of seizure and adverse effects of therapy were encountered rarely. No risk factors for persistent seizure could be identified. Present study shows that the response to cysticidal therapy is very good in NCC as seizure recurrence was observed in only 5%, 4.2%, and 4.2% of cases at 3-month, 6-month, and 1-year followup. Adverse effects of therapy were observed in 20% of cases during therapy but they were mild and self-limiting.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259654PMC
http://dx.doi.org/10.1155/2017/8983958DOI Listing

Publication Analysis

Top Keywords

cysticidal therapy
12
adverse effects
12
response cysticidal
8
therapy
8
risk factors
8
factors persistent
8
persistent seizure
8
therapy good
8
effects therapy
8
seizure
6

Similar Publications

Acanthamoeba species are responsible for serious human infections, including Acanthamoeba keratitis (AK) and granulomatous amoebic encephalitis (GAE). These pathogens have a simple life cycle consisting of an infective trophozoite stage and a resistant cyst stage, with cysts posing significant treatment challenges due to their resilience against harsh conditions and chemical agents. Current treatments for AK often involve combining diamines, such as propamidine, and biguanides, such as chlorhexidine (CLX), which exhibit limited efficacy and significant toxicity.

View Article and Find Full Text PDF

Aims: Spinal neurocysticercosis is a rare central nervous system infection caused by the larval form of the . Due to its rarity, most knowledge is derived from isolated case reports. This review aims to evaluate existing case reports and observational studies to provide a comprehensive overview of the disease's clinical presentation and treatment outcomes.

View Article and Find Full Text PDF

Background: Acanthamoebae are causative agents of severe and complicated human infections without a standard effective therapy to date. Therefore, the research is focused on the development of new amoebicidal drugs based on the natural products. Plants of the family Lamiaceae are typical with several phenolic secondary metabolites that make them interesting in medical point of view.

View Article and Find Full Text PDF

Management of calcified cysticerci in the brain parenchyma: treating the dead parasite.

Expert Rev Anti Infect Ther

December 2024

School of Medicine and Research Center, Universidad Espíritu Santo - Ecuador, Samborondón, Ecuador.

Introduction: Calcifications are the end stage of many parenchymal brain cysticerci and may occur either spontaneously or as the result of treatment with cysticidal drugs. These lesions, traditionally considered inert and asymptomatic, have been associated with several complications that seem to be mostly related to brain damage and inflammation ensuing as the result of the exposure of the host's immune system to parasitic antigens trapped within calcifications.

Areas Covered: This review, based on the search of different electronic databases up to May 2024, focuses on the reported correlates and complications of calcified cysticerci (chronic headaches, seizures/epilepsy, hippocampal atrophy/sclerosis, gliomas), and the different interventions developed for their prevention and treatment.

View Article and Find Full Text PDF
Article Synopsis
  • * A study involving 104 patients assessed how the immune response affects the effectiveness of AHD therapy by measuring cytokine levels in blood samples before and after treatment.
  • * Results showed that responders to treatment had lower IL-10 and IL-6 levels after AHD, while non-responders had higher levels, suggesting that these cytokines may play a role in the treatment's success.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!